David Malka

21.9k citations
290 papers · 16.2k · 9 hit papers · h-index 68

Impact in

  • Oncology top 0.2%
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
    • Colorectal Cancer Surgical Treatments
    • Cancer Immunotherapy and Biomarkers
  • Surgery top 0.2%
    • Cholangiocarcinoma and Gallbladder Cancer Studies
    • Intraperitoneal and Appendiceal Malignancies

Papers in

    • Colorectal Cancer Treatments and Studies 64
    • Pancreatic and Hepatic Oncology Research 40
    • Colorectal Cancer Surgical Treatments 12
    • Cholangiocarcinoma and Gallbladder Cancer Studies 55
    • Intraperitoneal and Appendiceal Malignancies 24

David Malka

275 papers receiving 15.8k citations

David Malka's Hit Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial 2023 · 728 citations
7280+7+14Years since publication5001k1.5k2k

Peers

David Malka
Comparison fields: 5 of 126
  • Oncology 6.2k
  • Surgery 4.8k
  • Hepatology 917
  • Dermatology 457
  • Pulmonary and Respiratory Medicine 1.2k
Replace Valérie Boige with:
Valérie Boige France
Marina Talamonti United States
Bruno Vincenzi Italy
Jae‐Lyun Lee South Korea
John A. Bridgewater United Kingdom
Laura Rubbia‐Brandt Switzerland
Steven R. Alberts United States
Tsung‐Teh Wu United States
Pascal R. Hammel France
Philip B. Paty United States
David Malka relative to Valérie Boige France Valérie Boige's profile →
Citations per field
00.5×1.5×
Valérie Boige · 1×
Citations per year

Countries citing papers authored by David Malka

Since Specialization
Citations

This map shows the geographic impact of David Malka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Malka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Malka more than expected).

Fields of papers citing papers by David Malka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Malka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Malka. The network helps show where David Malka may publish in the future.

Co-authors

The 25 scholars most cited alongside David Malka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Malka Line = papers co-authored together David Malka links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 290 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Hit paper breakdown →
20182184
2
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2023728
3
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Hit paper breakdown →
2005440
4
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hit paper breakdown →
2022417
5
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Hit paper breakdown →
2019410
6
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies
Hit paper breakdown →
2020391
7 2002353
8
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
Hit paper breakdown →
2014337
9 2006285
10 2013275
11 2000253
12
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Hit paper breakdown →
2022225
13 2013210
14 2014209
15 2005205
16 2010182
17
Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study
Hit paper breakdown →
2020175
18 2019173
19 2011172
20 2007170

About David Malka

David Malka is a scholar working on Oncology, Surgery, Hepatology, Pathology and Forensic Medicine and Epidemiology, having authored 290 papers that have together received 16.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (64 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (55 papers), Pancreatic and Hepatic Oncology Research (40 papers), Intraperitoneal and Appendiceal Malignancies (24 papers), Neuroendocrine Tumor Research Advances (20 papers), Genetic factors in colorectal cancer (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers) and Colorectal Cancer Surgical Treatments (12 papers). The work is most often cited by research in Oncology (6.2k citations), Surgery (4.8k citations), Hepatology (917 citations), Dermatology (457 citations) and Pulmonary and Respiratory Medicine (1.2k citations). David Malka has collaborated with scholars based in France, Germany and United States. Frequent co-authors include Michel Pierre Ducreux, Valérie Boige, Dominique M. Elias, Diane Goèré, Clarisse Dromain, Thierry de Baère, Philippe B Ruszniewski, Julien Taı̈eb, Pascal R. Hammel and Jean‐Charles Soria. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, The Lancet Oncology and Annals of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact